Neuphoria Therapeutics (NEUP) Return on Capital Employed [ROCE] (2024 - 2026)
Neuphoria Therapeutics (NEUP) recorded Return on Capital Employed [ROCE] of -53.06% in fiscal Q4 2026 (quarter ended Jun 30, 2026), down 48.62 percentage points from -4.44% a year earlier and down 4.04 percentage points from the prior quarter.
Powered by 
Analysis
Neuphoria Therapeutics (NEUP) Return on Capital Employed [ROCE] (2024 - 2026) Analysis & Trends
For FY2026 (ended Jun 30, 2026), Neuphoria Therapeutics reported Return on Capital Employed [ROCE] of -58.98%, down 54.26 percentage points from FY2025.
- Annual Return on Capital Employed [ROCE] has a five-year change of -29.51 percentage points (FY2021 to FY2026).
- Across earlier fiscal years, Return on Capital Employed [ROCE] came in at -4.72% in FY2025 (+68.98 pp), -73.70% in FY2024 (-12.43 pp), -61.27% in FY2023 (-23.80 pp) and -37.47% in FY2022 (-8.00 pp).
- The fiscal Q4 2026 figure is the lowest quarterly Return on Capital Employed [ROCE] since fiscal Q2 2025.
- On a year-over-year basis, Return on Capital Employed [ROCE] rose in two of the last four quarters, with an average year-over-year change of +8.03 percentage points.
- Per Business Quant, the preceding three fiscal quarters came in at -49.02% (Q3 2026), -12.15% (Q2 2026) and -14.07% (Q1 2026).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 46.74% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 17.83% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 17.92% |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.28% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 19.32% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 9.54% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 16.66% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -5.97% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 11.86% |
| 10 | Neuphoria Therapeutics | 431.33 Mn | 356.14 Mn | - | -53.06% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -53.06% |
| Mar 31, 2026 | -49.02% |
| Dec 31, 2025 | -12.15% |
| Sep 30, 2025 | -14.07% |
| Jun 30, 2025 | -4.44% |
| Mar 31, 2025 | -3.37% |
| Dec 31, 2024 | -82.26% |
| Sep 30, 2024 | -70.35% |
API Access
Neuphoria Therapeutics Return on Capital Employed [ROCE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=NEUP&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-capital-employed-[roce]", "ticker": "NEUP", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=NEUP&period=max&api_key=YOUR_API_KEY");
const data = await res.json();